Another study conducted in both prostate cancer cells and TRAMP mice have demonstrated that SFN treatment can effectively inhibit the growth of prostate cancer by reducing plasma lactate levels in the prostate and down-regulating the levels of glycolysis-related proteins HK2, pyruvate kinase isozymes M2 (PKM2), and lactate dehydrogenase A (LDHA) (Singh et al. 2019). The gene discussed is HK2; the disease is prostate carcinoma.